Ethical and Clinical Considerations in Ordering and Responding to Molecular Diagnostics and Circulating Tumor DNA as the Science Evolves.

The article focuses on the ethical, clinical, and regulatory challenges of using molecular diagnostic tests, such as circulating tumor DNA (ctDNA), in cancer care. Topics include the evolving role of ctDNA testing in detecting minimal residual disease, the ethical considerations surrounding early adoption of tests with uncertain clinical benefits, and the responsibility of oncologists in guiding patients through emerging technologies.